179 related articles for article (PubMed ID: 10554007)
1. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis.
Shaheen RM; Davis DW; Liu W; Zebrowski BK; Wilson MR; Bucana CD; McConkey DJ; McMahon G; Ellis LM
Cancer Res; 1999 Nov; 59(21):5412-6. PubMed ID: 10554007
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms.
Shaheen RM; Tseng WW; Davis DW; Liu W; Reinmuth N; Vellagas R; Wieczorek AA; Ogura Y; McConkey DJ; Drazan KE; Bucana CD; McMahon G; Ellis LM
Cancer Res; 2001 Feb; 61(4):1464-8. PubMed ID: 11245452
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
[TBL] [Abstract][Full Text] [Related]
4. Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis.
Shaheen RM; Tseng WW; Vellagas R; Liu W; Ahmad SA; Jung YD; Reinmuth N; Drazan KE; Bucana CD; Hicklin DJ; Ellis LM
Int J Oncol; 2001 Feb; 18(2):221-6. PubMed ID: 11172585
[TBL] [Abstract][Full Text] [Related]
5. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
[TBL] [Abstract][Full Text] [Related]
6. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
7. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
8. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.
Fong TA; Shawver LK; Sun L; Tang C; App H; Powell TJ; Kim YH; Schreck R; Wang X; Risau W; Ullrich A; Hirth KP; McMahon G
Cancer Res; 1999 Jan; 59(1):99-106. PubMed ID: 9892193
[TBL] [Abstract][Full Text] [Related]
9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
10. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM
Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244
[TBL] [Abstract][Full Text] [Related]
11. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response.
Griffin RJ; Williams BW; Wild R; Cherrington JM; Park H; Song CW
Cancer Res; 2002 Mar; 62(6):1702-6. PubMed ID: 11912143
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
15. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
Abdollahi A; Lipson KE; Han X; Krempien R; Trinh T; Weber KJ; Hahnfeldt P; Hlatky L; Debus J; Howlett AR; Huber PE
Cancer Res; 2003 Jul; 63(13):3755-63. PubMed ID: 12839971
[TBL] [Abstract][Full Text] [Related]
16. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
Prewett M; Huber J; Li Y; Santiago A; O'Connor W; King K; Overholser J; Hooper A; Pytowski B; Witte L; Bohlen P; Hicklin DJ
Cancer Res; 1999 Oct; 59(20):5209-18. PubMed ID: 10537299
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
Davis DW; Takamori R; Raut CP; Xiong HQ; Herbst RS; Stadler WM; Heymach JV; Demetri GD; Rashid A; Shen Y; Wen S; Abbruzzese JL; McConkey DJ
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):678-89. PubMed ID: 15701856
[TBL] [Abstract][Full Text] [Related]
18. NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
Nishikawa M; Stapleton PP; Freeman TA; Gaughan JP; Matsuda T; Daly JM
J Am Coll Surg; 2004 Sep; 199(3):428-35. PubMed ID: 15325613
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.
Geng L; Donnelly E; McMahon G; Lin PC; Sierra-Rivera E; Oshinka H; Hallahan DE
Cancer Res; 2001 Mar; 61(6):2413-9. PubMed ID: 11289107
[TBL] [Abstract][Full Text] [Related]
20. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
